BRITE-MARK BLACK

SECTION 2: Hazards identification

SAFE OPERATING CONDITIONS ARE ESTABLISHED AND MAINTAINED. EMERGENCY OVERVIEW:

Storage

BLACK OPAQUE THIN VISCOSITY LIQUID WITH SWEET ODOR. KEEP AWAY FROM HEAT, SPARKS AND OPEN FLAMES, KEEP OUI OF REACH OF CHILDREN. KEEP CONTAINER TIGHTLY SCALED WHEN NOT IN USE. STORE IN CooL WARNING! WELL-VENTILATED PLACE AWAY FROM INCOMPATIBLE MATERIALS. INFORMATION ON THIS MATERIAL SAFETY DATA SHEETS REFERS TO INK USED IN PENS AND MARKERS, HOWEVER, FLAMMABLE LIQUID AND VAPOR. KEEP AWAY FROM HEAT SPARKS AND FLAMES. MAY CAUSE IT APPLIES TO THESE INKS IN BULK. THE INKS ARE CONTAINED IN CAPILLARY OR EYE, SKIN AND RESPIRATORY TRACT IRRITATION, IF SWALLOWED DO NOT INDUCE VALVE RESERVOIRS AND WILL NOT SPILL OR LEAK UNDER NORMAL CONDITIONS. VOMITING. GET IMMEDIATE MEDICAL ATTENTION.

Potential health effects

SECTION 8 EXPOSURE CONTROLS/PERSONAL PROTECTION EYES: LIQUID IS MODERATELY IRRITATING TO THE EYES. RESPIRATORY PROTECTION (SPECIFY TYPE) : NOT USUALLY NECESSARY. USE WI'TH ADEQUATE VENTILATION. USE NIOSH/MSHA SKIN: LIQUID IS MILDLY IRRITATING TO THE SKIN. APPROVED RESPIRATOR IF PELS OR TLVS ARE EXCEEDED. INGESTION: INGESTION OF LIQUID MAY CAUSE VOMITING. ENGINEERING CONTROLS: LOCAL EXHAUST: NOT USUALLY NEEDED INHALATION HIGH CONCENTRATION OF VAPORS MAY PRODUCE IRRITATION OF THE RESPIRATORY MECHANICAL (GENERAL): YES TRACT, HEADACHE, DIZZINESS, AND NAUSEA.

Potential chronic health

PROTECTIVE GLOVES: PROLONGED OR REPEATED CONTACT MAY CAUSE SKIN SENSITIZATION OR DERMATITIS. CHEMICAL RESISTANT GLOVES IF SKIN CONTACT IS POSSIBLE (CONSULT YOUR SAFETY REPORTS HAVE ASSOCIATED REPEATED AND PROLONGED OCCUPATIONAL OVEREXPOSURE EQUIPMENT SUPPLIER) . SOLVENTS WITH IRREVERSIBLE BRAIN AND NERVOUS SYSTEM DAMAGE. INTENTIONAL MISUSE BY DELIBERATELY CONCENTRATING OR INHALING THIS PRODUCT MAY BE HARMFUL EYE PROTECTION: OR FATAL, IARC (INTERNATIONAL AGENCY FOR RESEARCH OF CANCER) HAS CLASSIFIED NOT NORMALLY REQUIRED IF USED AS INTENDED. WEAR CHEMICAL SPLASH GOGGLES IN CARBON BLACK AS A POSSIBLE HUMAN CARCINOGEN (2B). COMPLIANCE WITH